The FDA Doxil Label contains a box warning that acute infusion-related reactions, occurred in up to 10% of patients. The reactions are serious and sometimes fatal allergic/anaphylactoid-like complications. Medications/emergency equipment to treat such reactions should be available for immediate use.
These infusion reactions are induced by complement activation (Complement Activation Related Pseudo Allergy - CARPA). Recently we developed a simple complement test that may predict the possible "allergic" reaction from the serum of the patient. Basically the test is the modification of the clinical complement fixation test. If you plan Doxil treatment for your patient please contact us and we tranfer the assay protocol free of charge.